

Drug Monograph

Drug Name: **Asceniv™ (immune globulin intravenous, human - slra) injection**
 Drug Class: **Immunodeficiency Agent**
 Prepared For: MO HealthNet
 Prepared By: Conduent

New Criteria **Revision of Existing Criteria**

Executive Summary

Purpose: The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.

Dosage Forms: Asceniv is available as a liquid solution containing 10% IgG for IV infusion. The 50 mL solution contains 100 mg/mL IgG.

Manufacturer: ADMA Biologics, Boca Raton, FL 33487

Indications: Asceniv is now approved for adults and adolescents, age 12 to 17, for primary humoral immunodeficiency (PI).

Costs: \$4,500 per 50 mL vial of Asceniv solution for injection. *Wholesale Acquisition Cost*

Summary of Findings: MO HealthNet Division recommends Open Access status for this product.

Status Recommendation: Clinical Edit PA Required
 Open Access PDL

Type of PA Criteria: Appropriate Indications Non-Preferred
 No PA Required Preferred

Prepared by: Tyler Woods PharmD
 Date: January 3, 2020